6533b81ffe1ef96bd1278784
RESEARCH PRODUCT
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Nick ThatcherMartin ReckRolf KaiserLuis Paz-aresKeunchil ParkNick PavlakisFrank HilbergJosé BarruecoChristian GrohéChristian ManegoldRudolf M. HuberSanjay PopatKeith M. Kerrsubject
0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung NeoplasmsTime FactorsBevacizumabmedicine.medical_treatmentDocetaxelAntibodies Monoclonal HumanizedDisease-Free SurvivalRamucirumab03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerLungChemotherapybusiness.industryPatient SelectionAntibodies MonoclonalGeneral Medicinemedicine.diseaserespiratory tract diseasesBevacizumab030104 developmental biologyOncologychemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionAdenocarcinomaNintedanibNivolumabbusinessmedicine.drugdescription
A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has ‘aggressive disease’, as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression. Based on a review of the clinical data, we recommend aggressive nonsquamous NSCLC should be defined by progression within <6–9 months of first-line treatment initiation.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-04-01 | Future oncology (London, England) |